Chewable Tablet Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The licence and approval architecture for a chewable tablet manufacturing facility spans CDSCO formulation licensing, FSSAI compliance where nutraceutical or food-supplement claims are embedded, and environmentalclearance thresholds that trigger EIA Notification 2006 applicability. Schedule M GMP requirements apply to the full production environment, with specific provisions for chewable tablet-specificattributes like taste-masking validation and chew-force testing.

• CDSCO Form 27B / Schedule M Compliance: Manufacturing licence for chewable tablets under Drugs and Cosmetics Act 1940. Application via SUGAM portal. Facility must demonstrate GMP compliance through Schedule M I, II, III documentation. SiteMaster File must detail chewable-specific process validation protocols including taste-masking and disintegration time specifications.
• FSSAI Product Approval (if nutraceutical claims): Chewable supplements marketed with health claims require FSSAI product approval under Food Safety and Standards Act 2006. Product-specific safety assessment by FSSAI empanelled laboratories. Label claim compliance with Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use) Regulations 2016.
• BIS IS 10648 Certification: Bureau of Indian Standards specification IS 10648 (Part 1 and Part 2) applies to calcium carbonate and mineral supplement chewables. BIS licensing is mandatory where product standards have been notified under the BIS Act 2016. Testing at BIS empanelled laboratories.
• Pollution Control Board Consent: Consent to Establish (CTE) from State Pollution Control Board under Water Act 1974 and Air Act 1981. EIA Notification 2006 applicability if land area exceeds 50,000 sqm or if located within 10 km of Critically Polluted Areas (CPAs). Environmental Impact Assessment (EIA) with public consultation for greenfield facilities above threshold capacity.
• Factory Licence under Factories Act 1948: State Factory Inspectorate registration mandating compliance with sections 6, 7, 79 on health, safety, and welfare provisions. Specific provisions for pharmaceutical manufacturing environments including air-quality monitoring, cross-contamination controls, and occupational health surveillance.
• GST Registration and MSME Udyam Enrolment: GST registration via GSTN portal. MSME Udyam Registration for plant classified under NIC Code 21001 (Manufacture of pharmaceutical products) enables access to priority-sector lending and applicable state MSME incentives.
• Drug Licence Import-export provisions: For facilities supplying US FDA-approved or EU GMP-certified formulations, respective regulatory body registration. WHO-GMP certification enhances export market access and may qualify facility for PLI Scheme incentives under production-linked incentive structure.
• Schedule M Environmental Controls: Specific pharmaceutical manufacturing environmental parameters under Schedule M including temperature-humidity controls in production areas (21°C +/- 2°C, 45% RH), HEPA filtration requirements for oral dosage forms, and continuous environmental monitoring documentation.

KAMRIT Financial Services LLP manages the end-to-end regulatory filing architecture for this project: from CDSCO SUGAM submissions and Schedule M documentation through FSSAI product approval applications, BIS licensing coordination, and Pollution Control Board consent management. Our team engages directly with CDSCO zonal offices, FSSAI empanelled consultants, and State Pollution Control Boards to compress approval timelines and minimise first-mover compliance risk for project commissioning.

The chewable tablet sub-segment differentiates from standard oral solid dosage through specific palatability, texture, and disintegration requirements that shape both formulation science and manufacturing equipment selection. Within the broader pharma and healthcare market, chewables occupy the overlap between therapeutic compliance and consumer-health positioning: antacid formulations like Digene (Abbott) and Gelusil trade at consumer-health margin profiles, while calcium and vitamin chewables like Shelcal operate more like mass-pharma SKUs with higher volume throughput expectations. Market segmentation within chewables reveals differentiated growth rate gradients.

Calcium and mineral supplements, driven by osteoporosis prevalence and bone-health awareness, represent the fastest-growing sub-segment with estimated 15-17% annual growth. Vitamin B-complex and multivitamin chewables are growing at 12-14%, anchored by preventive healthcare adoption in urban and semi-urban markets. Antacid and digestive-health chewables are growing at 8-10%, constrained by lifestyle-disease awareness saturation in metros.

Paediatric formulations, including antibiotic and analgesic chewables, are growing at 10-12%, driven by acceptability advantages over syrups. Weight-management and sports-nutrition chewables represent the emerging sub-segment with 18-22% growth, though from a smaller base. The competitive landscape is structurally layered.

Cipla commands shelf-space dominance in calcium chewables through institutional prescribing relationships and chemist-network reach. Amway India operates a D2C-first model through its distributor network, creating a distinct channel-mix challenge for institutional manufacturers seeking retail placement. Mankind Pharma's Ostocalcium competes on value pricing and rural penetration.

Abbott's Digene and Enfied (Glenmark) operate in the antacid niche with higher brand-marketing intensity. Mascot, a regional Tier-2 player, has demonstrated that national-distribution ambition is achievable with consistent supply-quality performance.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

Chewable tablet manufacturing requires a distinct equipment architecture that balances formulation flexibility with cost-competitive production economics. The core production line comprises: high-shear granulation systems for taste-masking API embedding, fluidised-bed dryers for moisture-controlled granule production, tablet presses with specialised punch configurations for shallow-convex chewable geometries, and coating systems for final taste-masking layers where applicable. Equipment sourcing decisions significantly impact CapEx profiles and output cost structures.

German equipment (FETTE, Korsch) offers superior tablet press precision and extended die-punch life, commanding ₹2.5-4 crore per compression machine for high-throughput lines. Japanese equipment (Kikusui, Sejong) provides intermediate value positioning at ₹1.5-2.5 crore per machine. Chinese equipment (Zhangjiagang, Shanghai) enables lowest CapEx entry at ₹0.8-1.5 crore per machine, though higher maintenance overheads and process-validation complexity offset initial savings.

Indian equipment manufacturers like S. B. Panchal and Rimek offer ₹0.5-1 crore granulation and tableting solutions suitable for capacities below 50 million tablets per annum.

For a 100 million tablets per annum facility, a two-line configuration (one primary high-speed press, one secondary or dedicated to specific SKU batches) delivers optimal CapEx efficiency. Total equipment cost for an Indian-manufactured line with selective German components ranges from ₹2.5-4 crore. Energy consumption benchmarks for chewable tablet production: approximately 150-200 kWh per million tablets, with thermal energy for granulation and drying accounting for 40-45% of total energy cost.

Water consumption for a pharmaceutical-grade facility with in-house water-for-injection (WFI) generation: approximately 50-80 kilolitres per day depending on batch-size configuration. Output-cost benchmarks: material cost constitutes 55-65% of production cost for most chewable formulations, with API and excipient costs varying significantly by therapeutic category. Conversion cost (direct labour, utilities, overhead allocation) ranges from ₹0.15-0.35 per tablet for well-utilised facilities operating above 70% nameplate capacity.

At current market pricing for common chewable categories, gross margins of 35-55% are achievable depending on brand positioning and channel mix.

For a chewable tablet plant project at ₹4.9 crore - ₹86 crore CapEx with a 3.6 - 5.4-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

For chewable tablet plant at ₹4.9 crore - ₹86 crore CapEx and 3.6 - 5.4-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For this category specifically, KAMRIT also models supplier concentration risk, currency exposure where input-imports exceed 25 percent of CapEx, and the working-capital cycle stretch in the first 18 months of commissioning. The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.